ANI PHARMACEUTICALS, INC Amortization of Debt Discount (Premium)
ANI PHARMACEUTICALS, INC (ANIP) reported Amortization of Debt Discount (Premium) of $0 for the 3-month period ending 2020-03-31, per its 10-Q filed 2020-05-07.
Discontinued › Cash Flow › Operating Activities
us-gaap:AmortizationOfDebtDiscountPremium · last filed 2022-03-15
- ANI PHARMACEUTICALS, INC amortization of debt discount (premium) for the quarter ending 2020-03-31 was $0.00, a 100.00% decline year-over-year.
- ANI PHARMACEUTICALS, INC amortization of debt discount (premium) for the quarter ending 2019-12-31 was $1.05M, a 39.20% decline year-over-year.
- ANI PHARMACEUTICALS, INC amortization of debt discount (premium) for the quarter ending 2019-09-30 was $1.55M, a 12.90% decline year-over-year.
- ANI PHARMACEUTICALS, INC amortization of debt discount (premium) for the quarter ending 2019-06-30 was $1.53M, a 12.84% decline year-over-year.
- ANI PHARMACEUTICALS, INC amortization of debt discount (premium) for fiscal 2019 was $5.65M, a 19.35% decline from fiscal 2018.
- ANI PHARMACEUTICALS, INC amortization of debt discount (premium) for fiscal 2018 was $7.00M, a 4.20% increase from fiscal 2017.
- ANI PHARMACEUTICALS, INC amortization of debt discount (premium) for fiscal 2017 was $6.72M, a 5.46% increase from fiscal 2016.
- ANI PHARMACEUTICALS, INC amortization of debt discount (premium) for fiscal 2016 was $6.37M, a 5.44% increase from fiscal 2015.
| Period end | Amortization of Debt Discount (Premium) 3 month | Amortization of Debt Discount (Premium) 6 month | Amortization of Debt Discount (Premium) 9 month | Amortization of Debt Discount (Premium) 12 month |
|---|---|---|---|---|
| 2020-03-31 | $0.00 10-Q · filed 2020-05-07 | $1.05M derived: sum of 2 quarters · filed 2022-03-15 | $2.60M derived: sum of 3 quarters · filed 2022-03-15 | $4.13M derived: sum of 4 quarters · filed 2022-03-15 |
| 2019-12-31 | $1.05M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | $2.60M derived: sum of 2 quarters · filed 2022-03-15 | $4.13M derived: sum of 3 quarters · filed 2022-03-15 | $5.65M 10-K · filed 2022-03-15 |
| 2019-09-30 | $1.55M 10-Q · filed 2020-11-05 | $3.09M derived: sum of 2 quarters · filed 2020-11-05 | $4.60M 10-Q · filed 2020-11-05 | $6.32M derived: sum of 4 quarters · filed 2021-03-11 |
| 2019-06-30 | $1.53M 10-Q · filed 2020-08-06 | $3.05M 10-Q · filed 2020-08-06 | $4.77M derived: sum of 3 quarters · filed 2021-03-11 | $6.55M derived: sum of 4 quarters · filed 2021-03-11 |
| 2019-03-31 | $1.51M 10-Q · filed 2020-05-07 | $3.23M derived: sum of 2 quarters · filed 2021-03-11 | $5.02M derived: sum of 3 quarters · filed 2021-03-11 | $6.78M derived: sum of 4 quarters · filed 2021-03-11 |
| 2018-12-31 | $1.72M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | $3.50M derived: sum of 2 quarters · filed 2021-03-11 | $5.26M derived: sum of 3 quarters · filed 2021-03-11 | $7.00M 10-K · filed 2021-03-11 |
| 2018-09-30 | $1.78M 10-Q · filed 2019-11-06 | $3.54M derived: sum of 2 quarters · filed 2019-11-06 | $5.28M 10-Q · filed 2019-11-06 | $6.99M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-06-30 | $1.76M 10-Q · filed 2019-08-07 | $3.50M 10-Q · filed 2019-08-07 | $5.21M derived: sum of 3 quarters · filed 2020-02-27 | $6.90M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-03-31 | $1.74M 10-Q · filed 2019-05-09 | $3.45M derived: sum of 2 quarters · filed 2020-02-27 | $5.14M derived: sum of 3 quarters · filed 2020-02-27 | $6.81M derived: sum of 4 quarters · filed 2020-02-27 |
| 2017-12-31 | $1.71M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $3.40M derived: sum of 2 quarters · filed 2020-02-27 | $5.07M derived: sum of 3 quarters · filed 2020-02-27 | $6.72M 10-K · filed 2020-02-27 |
| 2017-09-30 | $1.69M 10-Q · filed 2018-11-06 | $3.36M derived: sum of 2 quarters · filed 2018-11-06 | $5.01M 10-Q · filed 2018-11-06 | $6.63M derived: sum of 4 quarters · filed 2019-02-27 |
| 2017-06-30 | $1.67M 10-Q · filed 2017-08-03 | $3.31M 10-Q · filed 2018-08-07 | $4.94M derived: sum of 3 quarters · filed 2019-02-27 | $6.54M derived: sum of 4 quarters · filed 2019-02-27 |
| 2017-03-31 | $1.65M 10-Q · filed 2018-05-08 | $3.27M derived: sum of 2 quarters · filed 2019-02-27 | $4.88M derived: sum of 3 quarters · filed 2019-02-27 | $6.46M derived: sum of 4 quarters · filed 2019-02-27 |
| 2016-12-31 | $1.62M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | $3.23M derived: sum of 2 quarters · filed 2019-02-27 | $4.81M derived: sum of 3 quarters · filed 2019-02-27 | $6.37M 10-K · filed 2019-02-27 |
| 2016-09-30 | $1.60M 10-Q · filed 2017-11-02 | $3.19M derived: sum of 2 quarters · filed 2017-11-02 | $4.75M 10-Q · filed 2017-11-02 | $6.29M derived: sum of 4 quarters · filed 2018-02-27 |
| 2016-06-30 | $1.58M 10-Q · filed 2017-08-03 | $3.14M 10-Q · filed 2017-08-03 | $4.68M derived: sum of 3 quarters · filed 2018-02-27 | $6.21M derived: sum of 4 quarters · filed 2018-02-27 |
| 2016-03-31 | $1.56M 10-Q · filed 2017-05-04 | $3.10M derived: sum of 2 quarters · filed 2018-02-27 | $4.62M derived: sum of 3 quarters · filed 2018-02-27 | $6.13M derived: sum of 4 quarters · filed 2018-02-27 |
| 2015-12-31 | $1.54M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | $3.06M derived: sum of 2 quarters · filed 2018-02-27 | $4.56M derived: sum of 3 quarters · filed 2018-02-27 | $6.04M 10-K · filed 2018-02-27 |
| 2015-09-30 | $1.52M 10-Q · filed 2016-11-03 | $3.02M derived: sum of 2 quarters · filed 2016-11-03 | $4.50M 10-Q · filed 2016-11-03 | |
| 2015-06-30 | $1.50M 10-Q · filed 2016-08-04 | $2.98M 10-Q · filed 2016-08-04 | ||
| 2015-03-31 | $1.48M 10-Q · filed 2016-05-05 | |||
| 2014-12-31 | $489.00K 10-K · filed 2016-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |